151 related articles for article (PubMed ID: 32780899)
1. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials.
Seeto AH; Abrahamsen B; Ebeling PR; Rodríguez AJ
J Bone Miner Res; 2021 Jan; 36(1):24-40. PubMed ID: 32780899
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials.
Catton B; Surangiwala S; Towheed T
Int J Rheum Dis; 2021 Jul; 24(7):869-879. PubMed ID: 33793076
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
6. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
7. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.
Lv F; Cai X; Yang W; Gao L; Chen L; Wu J; Ji L
Bone; 2020 Jan; 130():115121. PubMed ID: 31678488
[TBL] [Abstract][Full Text] [Related]
8. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.
Seeto AH; Tadrous M; Gebre AK; Lewis JR; Fink HA; Ebeling PR; Rodríguez AJ
Bone; 2023 Feb; 167():116610. PubMed ID: 36372197
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
13. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis.
Diker-Cohen T; Rosenberg D; Avni T; Shepshelovich D; Tsvetov G; Gafter-Gvili A
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31899506
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
15. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T; Morimoto T; Ito K; Mawatari M; Shimazaki T
Osteoporos Int; 2024 May; ():. PubMed ID: 38733394
[TBL] [Abstract][Full Text] [Related]
16. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
17. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Mar; 32(3):413-424. PubMed ID: 33145606
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
19. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]